UCB8600 / UCB - LARVOL DELTA

MASTGUT: Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Guy Boeckxstaens | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder

MASTGUT: Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Guy Boeckxstaens

New trial • Gastrointestinal Disorder

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - P1; N=40; Terminated; Sponsor: UCB Biopharma SRL; Trial completion date: Jul 2022 ➔ Aug 2021; Active, not recruiting ➔ Terminated; Trial primary completion date: Jul 2022 ➔ Aug 2021; internal company decision; not safety related

Clinical • Trial completion date • Trial primary completion date • Trial termination • Chronic Spontaneous Urticaria • Dermatology • Urticaria

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: UCB Biopharma SRL; Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Spontaneous Urticaria • Dermatology • Urticaria

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - P1; N=174; Recruiting; Sponsor: UCB Biopharma SRL; Trial completion date: Aug 2021 ➔ Jul 2022; Trial primary completion date: Aug 2021 ➔ Jul 2022

Clinical • Trial completion date • Trial primary completion date • Chronic Spontaneous Urticaria • Dermatology • Urticaria

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - P1; N=162; Recruiting; Sponsor: UCB Biopharma SRL; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Dermatology • Dermatopathology • Urticaria

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - P1; N=162; Not yet recruiting; Sponsor: UCB Biopharma SRL

Clinical • New P1 trial • Dermatology • Dermatopathology • Urticaria